SEATTLE, WA -- (MARKET WIRE) -- March 06, 2007 -- Targeted Genetics Corporation (NASDAQ: TGEN) today announced the issuance of an additional patent covering the company’s adeno-associated virus (AAV) vector technology. The patent, U.S. #7,186,552 titled “Adeno-Associated Virus (AAV) Serotype I Nucleic Acid Sequences, Vectors and Host Cells Containing Same” describes the use of AAV vectors that contain the inverted terminal repeat (ITR) and capsid sequences derived from AAV serotype 1 (AAV1) and host cells transduced with such vectors. The patent was issued to the University of Pennsylvania and is exclusively licensed to Targeted Genetics.
